IP Library Granted Patent US 11,229,620
Granted Patent B2
US 11,229,620 · App. 16/704,921 · Granted Jan 25, 2022

3-methanesulfonylpropionitrile for treating inflammation and/or pain

Inventor: Joseph St. Laurent (Lakeville, MA)
Assignee: Olatec Therapeutics LLC
A61K31/275A61K9/0014A61K9/0053A61K9/06A61K47/10C07C317/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,620
App. No.
16/704,921
Granted
Jan 25, 2022
Kind
B2
Abstract

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Claims (11)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of 3-methanesulfonylpropionitrile.

2. The pharmaceutical composition of claim 1 , wherein the compound is at least 90% (w/w) pure.

3. The pharmaceutical composition of claim 2 , wherein the compound is at least 95% (w/w) pure.

4. The pharmaceutical composition of claim 1 , in an oral form.

5. The pharmaceutical composition of claim 4 , wherein the oral form is a tablet or a capsule.

6. The pharmaceutical composition of claim 1 , in a topical form.

7. The pharmaceutical composition of claim 6 , wherein the topical form is a gel, cream, lotion, or patch.

8. The pharmaceutical composition according to claim 6 , wherein the compound is in an amount of about 0.5-10% (w/w).

9. The pharmaceutical composition according to claim 7 , wherein the pharmaceutically acceptable carrier is diethylene glycol monoethylether.

10. The pharmaceutical composition according to claim 9 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.

11. A method of treating inflammation and/or pain, both associated with an inflammatory skeletal or muscular disease or condition, comprising the steps of: identifying a subject in need thereof, and administering to the pharmaceutical composition of claim 1 , in an amount effective to treat the inflammation and/or pain, wherein the skeletal or muscular disease or condition is selected from the group consisting of: musculoskeletal sprains, musculoskeletal strains, gout, costochondritis, tendonitis, bursitis, and temporomandibular joint syndrome.

Assignments (1)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
Continuity (9)
Continuation 16139351 · Sep 24, 2018
Continuation 15712269 · Sep 22, 2017
Continuation 15349161 · Nov 11, 2016
Continuation 14639781 · Mar 5, 2015
Continuation 14216664 · Mar 17, 2014
Continuation 13759676 · Feb 5, 2013
Division 13324777 · Dec 13, 2011
Provisional Application 61423485 · Dec 15, 2010
Related Publication 20200237706A1 · Jul 30, 2020